Physician profile
Max T Hyatt
NPI 1417052143
$1,439.58
in general payments reported to CMS, 2019-2025
25 companies · $209 in 2025
The $209 reported for 2025 was less than what a typical Podiatrist provider received nationally (typical 2025 total: $260).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $188 · 2020: $37.13 · 2021: $87.94 · 2022: $48.78 · 2023: $427 · 2024: $442 · 2025: $209.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,078.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,077.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kerecis Limited | $193.49 | 2024-2025 | Kerecis Surgiclose, Kerecis Omega3 Marigen, Kerecis Graftguide |
| Convatec INC. | $171.47 | 2023-2024 | |
| Bioventus LLC | $125.00 | 2023 | Exogen Ultrasound Bone Healing System |
| Averitas Pharma INC. | $115.50 | 2023-2024 | Qutenza |
| Smith+Nephew, INC. | $101.58 | 2019-2025 | Hat-Trick, Evos Mini, Evos |
| Depuy Synthes Sales INC. | $93.02 | 2023-2024 | Motoband, Healix Knotless Peek, Vivigen Mis Delivery System |
| Organogenesis INC. | $92.78 | 2024-2025 | Apligraf |
| Integra Lifesciences Corporation | $76.67 | 2021 | |
| Horizon Therapeutics Plc | $75.52 | 2019-2023 | Krystexxa |
| Boston Scientific Corporation | $60.32 | 2023-2024 | Wavewriter Alpha Prime 16 |
| Merck Sharp & Dohme LLC | $45.07 | 2019 | |
| Abbvie INC. | $43.66 | 2022-2025 | |
| Amgen INC. | $30.49 | 2025 | Krystexxa |
| Fusion Orthopedics USA, LLC | $26.68 | 2024 | |
| Paratek Pharmaceuticals, INC. | $23.19 | 2023 | Nuzyra |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kci USA, INC. | $21.96 | 2020 | |
| Acell, INC. | $21.36 | 2019 | |
| Grt US Holding, INC. | $20.38 | 2022 | |
| Next Science LLC | $19.24 | 2023 | Surgx, Xperience, Blastx |
| Nevro Corp. | $18.12 | 2023 | Senza |
| Melinta Therapeutics, LLC | $15.27 | 2019 | |
| Globus Medical, INC. | $15.15 | 2025 | Senza |
| Pfizer INC. | $11.46 | 2019 | |
| Zyla Life Sciences, INC. | $11.46 | 2019 | |
| Wound Management Technologies, INC | $10.74 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Max Hyatt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.